Krawczyk Marcin, Stachowska Ewa, Milkiewicz Piotr, Lammert Frank, Milkiewicz Malgorzata
Department of Medicine II, Saarland University Medical Center, Homburg, Germany.
Digestion. 2016;93(2):139-48. doi: 10.1159/000441185. Epub 2016 Jan 9.
The adiponutrin (PNPLA3) p.I148M and transmembrane 6 superfamily member 2 (TM6SF2) p.E167K variants represent risk factors for non-alcoholic fatty liver disease (NAFLD). In this study, we assessed the effects of caloric restriction on liver phenotypes in NAFLD patients in relation to the PNPLA3 and TM6SF2 genotypes.
We genotyped both variants in 143 individuals with NAFLD (55 females, age 18-74 years) and 180 controls (85 females, age 33-66 years). Liver steatosis was assessed using the ultrasound-based Hamaguchi score. A 4-month dietetic intervention, consisting of restriction of daily caloric intake without changes in physical activity, was performed.
Both PNPLA3 (p = 0.002) and TM6SF2 (p = 0.041) variants were associated with NAFLD before intervention. Overall, 88 patients completed the intervention, which led to a significant decrease of steatosis, ALT activities, body mass index, hip and waist circumferences, and waist-hip ratio (all p < 0.0001). Hepatic steatosis and anthropometric traits improved significantly (p < 0.05) in carriers of either PNPLA3 or TM6SF2 risk genotype. The improvement of phenotypic traits, apart from WHR (p = 0.02), was not modified by the presence of PNPLA3 or TM6SF2 variants.
The PNPLA3 and TM6SF2 polymorphisms are associated with NAFLD assessed by the Hamaguchi score. Neither PNPLA3 nor TM6SF2 risk alleles impair the response to dietetic intervention in NAFLD.
脂肪营养素(PNPLA3)p.I148M和跨膜6超家族成员2(TM6SF2)p.E167K变异体是非酒精性脂肪性肝病(NAFLD)的危险因素。在本研究中,我们评估了热量限制对NAFLD患者肝脏表型的影响,并将其与PNPLA3和TM6SF2基因型相关联。
我们对143例NAFLD患者(55名女性,年龄18 - 74岁)和180名对照者(85名女性,年龄33 - 66岁)的这两种变异体进行了基因分型。使用基于超声的滨口评分评估肝脏脂肪变性。进行了为期4个月的饮食干预,包括限制每日热量摄入,而身体活动不变。
在干预前,PNPLA3(p = 0.002)和TM6SF2(p = 0.041)变异体均与NAFLD相关。总体而言,88例患者完成了干预,干预导致脂肪变性、丙氨酸转氨酶活性、体重指数、臀围和腰围以及腰臀比显著降低(所有p < 0.0001)。PNPLA3或TM6SF2风险基因型携带者的肝脂肪变性和人体测量特征有显著改善(p < 0.05)。除腰臀比(p = 0.02)外,表型特征的改善不受PNPLA3或TM6SF2变异体存在的影响。
PNPLA3和TM6SF2多态性与通过滨口评分评估的NAFLD相关。PNPLA3和TM6SF2风险等位基因均不损害NAFLD患者对饮食干预的反应。